<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02039817</url>
  </required_header>
  <id_info>
    <org_study_id>IDN-6556-05</org_study_id>
    <nct_id>NCT02039817</nct_id>
  </id_info>
  <brief_title>PK and PD Study of IDN-6556 in Subjects With Severe Renal Impairment and Matched Healthy Volunteers</brief_title>
  <official_title>An Open-Label Pharmacokinetic and Pharmacodynamic Study of a Single Dose of IDN-6556 in Subjects With Severe Renal Impairment and in Matched Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Conatus Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Conatus Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, parallel-group study to compare the pharmacokinetics and
      pharmacodynamics of IDN-6556 following a single 50 mg oral dose of IDN-6556 in subjects with
      severe renal impairment and matched healthy volunteers with normal renal function.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>48 hours</time_frame>
    <description>Area under the plasma concentration curve (AUC) parameters include AUC0-12, AUCinf, AUClast</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>48 hours</time_frame>
    <description>Maximum concentration (Cmax)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Levels of cCK18</measure>
    <time_frame>48 hours</time_frame>
    <description>Biomarker cCK18 (Cleaved cytokeratin 18) PK evaluations from pre-dose to 48 hours</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Renal Impairment</condition>
  <condition>Renal Insufficiency</condition>
  <condition>Kidney Disease</condition>
  <condition>Kidney Diseases</condition>
  <arm_group>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects receive a single 50 mg oral dose of IDN-6556</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects receive a single 50 mg oral dose of IDN-6556</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IDN-6556</intervention_name>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <arm_group_label>Severe Renal Impairment</arm_group_label>
    <other_name>emricasan</other_name>
    <other_name>PF-03491390</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All Subjects:

          -  Male or female subjects 18 - 75 years of age, able to provide written informed
             consent, understand and comply with all scheduled visits, and other requirements of
             the study

          -  Body mass index (BMI) 18.0 - 40.0 kg/m2 and body weight &gt;50 kg

          -  Willingness to utilize two reliable forms of contraception (for both males and females
             of childbearing potential) from screening to one month after the last dose of study
             drug

        Matched Healthy Volunteers:

          -  Medically healthy as determined by the Investigator

          -  Screening creatinine clearance ≥90 mL/min using the Cockcroft-Gault equation

          -  Supine blood pressure ≤145/90 mmHg

          -  No significant uncontrolled systemic or major illness that, in the opinion of the
             Investigator, would preclude the subject from participating in and completing the
             study

          -  Demographically comparable to subjects with severe renal impairment as follows:

               1. Mean body weight within ±10 kg

               2. Mean age within ±5 years

               3. Similar gender ratio

        Severe Renal Impaired Subjects:

          -  Screening creatinine clearance (CLCR) &lt;30 mL/min using the Cockcroft-Gault equation

          -  Supine blood pressure ≤170/110 mmHg

          -  Documented renal impairment indicated by reduced creatinine clearance within 12 months
             of screening or longer

          -  Stable renal function as evidenced by ≤30% difference in two measurements of
             creatinine clearance on two separate occasions separated by at least 28 days with one
             measurement being the value at screening.

        Exclusion Criteria:

          -  History of renal trasplant

          -  Acute renal failure

          -  Subjects undergoing any method of dialysis or hemofiltration

          -  Evidence or history of clinically significant uncontrolled hematological, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,
             seasonal allergies at time of dosing)

          -  Disorders or surgery of the gastrointestinal tract which may interfere with drug
             absorption or may otherwise influence the pharmacokinetics of the investigational
             medicinal product (e.g., inflammatory bowel disease, resections of the small or large
             intestine, etc.)

          -  History of febrile illness within 5 days prior to dosing

          -  Evidence of clinically significant liver disease or liver damage (e.g., hepatitis B or
             C, autoimmune hepatitis, primary biliary cirrhosis, non-alcoholic fatty liver disease,
             elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT) that is
             considered clinically significant by the Investigator, etc.)

          -  Known infection with human immunodeficiency virus (HIV) upon serological testing

          -  History or presence of clinically concerning cardiac arrhythmias, or prolongation of
             Screening (pre-treatment) QT or QTc interval of &gt;480 milliseconds (msec) for subjects
             with severe renal impairment or &gt;450 msec for matched healthy volunteers

          -  Subjects with active or history of malignancies other than curatively treated skin
             cancer (basal cell or squamous cell carcinomas)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dave Hagerty, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Conatus Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Avail Clinical Research</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2014</study_first_submitted>
  <study_first_submitted_qc>January 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2014</study_first_posted>
  <results_first_submitted>September 20, 2015</results_first_submitted>
  <results_first_submitted_qc>December 18, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 28, 2016</results_first_posted>
  <last_update_submitted>December 18, 2015</last_update_submitted>
  <last_update_submitted_qc>December 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetics</keyword>
  <keyword>pharmacodynamics</keyword>
  <keyword>renal impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was an open-label, multicenter, parallel-group study to compare the PK and PD of IDN 6556 following a single 50 mg oral dose of IDN-6556 in subjects with severe renal impairment and matched subjects with normal renal function (healthy volunteers).</recruitment_details>
      <pre_assignment_details>In total, 16 subjects were enrolled and dosed (8 subjects with severe renal impairment, and 8 healthy volunteers) with one 50mg dose of IDN-6556.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Healthy Volumteers</title>
          <description>Healthy volunteers were given a single 50mg dose of IDN-6556</description>
        </group>
        <group group_id="P2">
          <title>Severe Renal Impairment</title>
          <description>Severe Renal Impairment subjects were given a single 50mg dose of IDN-6556</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Healthy Volunteers</title>
          <description>Health Volunteers received one 50mg dose of IDN-6556</description>
        </group>
        <group group_id="B2">
          <title>Severe Renal Impairment</title>
          <description>Severe Renal Impairment subjects received one 50mg dose of IDN-6556</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.0" lower_limit="51" upper_limit="69"/>
                    <measurement group_id="B2" value="64.0" lower_limit="54" upper_limit="68"/>
                    <measurement group_id="B3" value="62.0" lower_limit="51" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AUC</title>
        <description>Area under the plasma concentration curve (AUC) parameters include AUC0-12, AUCinf, AUClast</description>
        <time_frame>48 hours</time_frame>
        <population>7 subjects were used in the calculation of AUC0-inf for the healthy volunteer group as one subject had no identifiable terminal log-linear phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Volunteers</title>
            <description>Subjects received a single 50 mg oral dose of IDN-6556</description>
          </group>
          <group group_id="O2">
            <title>Severe Renal Impairment</title>
            <description>Subjects received a single 50 mg oral dose of IDN-6556</description>
          </group>
        </group_list>
        <measure>
          <title>AUC</title>
          <description>Area under the plasma concentration curve (AUC) parameters include AUC0-12, AUCinf, AUClast</description>
          <population>7 subjects were used in the calculation of AUC0-inf for the healthy volunteer group as one subject had no identifiable terminal log-linear phase.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC 0-12 (h*ng/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102.0" spread="39.4"/>
                    <measurement group_id="O2" value="168.9" spread="42.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC 0-inf (h*ng/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.4" spread="41.3"/>
                    <measurement group_id="O2" value="188.5" spread="43.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC last (h*ng/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.9" spread="38.3"/>
                    <measurement group_id="O2" value="186.5" spread="43.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Levels of cCK18</title>
        <description>Biomarker cCK18 (Cleaved cytokeratin 18) PK evaluations from pre-dose to 48 hours</description>
        <time_frame>48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy Volunteers</title>
            <description>Subjects received a single 50 mg oral dose of IDN-6556</description>
          </group>
          <group group_id="O2">
            <title>Severe Renal Impairment</title>
            <description>Subjects received a single 50 mg oral dose of IDN-6556</description>
          </group>
        </group_list>
        <measure>
          <title>Levels of cCK18</title>
          <description>Biomarker cCK18 (Cleaved cytokeratin 18) PK evaluations from pre-dose to 48 hours</description>
          <units>U/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="240.0" lower_limit="165.5" upper_limit="336.0"/>
                    <measurement group_id="O2" value="223.5" lower_limit="155.0" upper_limit="288.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>.5 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="201.5" lower_limit="154.0" upper_limit="298.5"/>
                    <measurement group_id="O2" value="202.5" lower_limit="178.5" upper_limit="300.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208.0" lower_limit="154.5" upper_limit="266.0"/>
                    <measurement group_id="O2" value="191.5" lower_limit="183.0" upper_limit="283.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="202.5" lower_limit="157.0" upper_limit="234.0"/>
                    <measurement group_id="O2" value="198.0" lower_limit="175.5" upper_limit="284.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="184.5" lower_limit="140.5" upper_limit="210.0"/>
                    <measurement group_id="O2" value="201.0" lower_limit="190.5" upper_limit="295.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183.5" lower_limit="142.5" upper_limit="207.0"/>
                    <measurement group_id="O2" value="198.5" lower_limit="178.5" upper_limit="284.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179.0" lower_limit="141.5" upper_limit="232.0"/>
                    <measurement group_id="O2" value="221.5" lower_limit="162.0" upper_limit="291.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178.0" lower_limit="137.0" upper_limit="244.0"/>
                    <measurement group_id="O2" value="212.0" lower_limit="152.5" upper_limit="256.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167.0" lower_limit="132.0" upper_limit="220.0"/>
                    <measurement group_id="O2" value="205.5" lower_limit="155.0" upper_limit="266.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="204.0" lower_limit="144.0" upper_limit="286.5"/>
                    <measurement group_id="O2" value="192.5" lower_limit="159.5" upper_limit="266.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206.5" lower_limit="159.0" upper_limit="291.0"/>
                    <measurement group_id="O2" value="195.0" lower_limit="183.0" upper_limit="295.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax</title>
        <description>Maximum concentration (Cmax)</description>
        <time_frame>48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy Volunteers</title>
            <description>Subjects received a single 50 mg oral dose of IDN-6556</description>
          </group>
          <group group_id="O2">
            <title>Severe Renal Impairment</title>
            <description>Subjects received a single 50 mg oral dose of IDN-6556</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax</title>
          <description>Maximum concentration (Cmax)</description>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.5" spread="44"/>
                    <measurement group_id="O2" value="42.7" spread="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>10 Days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>IDN-6556</title>
          <description>A single 50mg dose of IDN-6556</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jean L. Chan, MD</name_or_title>
      <organization>Conatus Pharmaceuticals</organization>
      <phone>858 376 2632</phone>
      <email>jchan@conatuspharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

